In vitro and in vivo pharmacokinetics-pharmacodynamics of GV143253A, a novel trinem

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 2, 2003, Pages 770-776

  Ferrari, Livia ^a   Iavarone, Laura ^a   Braggio, Simone ^a   Di Modugno, Enza ^a  

^a GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GV 143253A; TRINEM DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THIGH;

ANIMALS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HALF-LIFE; LACTAMS; METHICILLIN RESISTANCE; MICE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0037311512     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.2.770-776.2003     Document Type: Article

References (18)

1. Alder, J. D. 1997. Determining the therapeutic potential of experimental antibacterial agents: the use of animal models. Curt. Pharm. Des. 3:143-158.
2. Chambers, H. F., M. Sachdeva, and S. Kennedy. 1990. Binding affinity for penicillin binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant S. aureus. J. Infect. Dis. 162:705-710.
3. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
4. Craig, W. A., J. Redington, and S. C. Ebert. 1991. Pharmacodynamic of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27(Suppl. C):29-40.
5. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
6. Drusano, G. L., and W. A. Craig. 1997. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J. Chemother. 9(Suppl. 3):38-44.
7. Healy, D. P., R. E. Polk, M. L. Garson, D. T. Rock, and T. J. Comstock. 1987. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob. Agents Chemother. 31:393-397.
8. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosada, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
9. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
10. Hyatt, J. M., P. S. McKinnon, G. S. Zimmer, and J. J. Schentag. 1995. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin. Pharmacokinet. 28:143-160.
11. Knudsen, J. D., K. Fuursted, F. Espersen, and N. Frimodt-Moller. 1997. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob. Agents Chemother. 41:1910-1915.
12. Knudsen, J. D., K. Fuursted, S. Raber, F. Espersen, and N. Frimodt-Moller. 2000. Pharmacodynamic of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob. Agents Chemother. 44:1247-1254.
13. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1991. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh infection and pneumonitis models. Scand. J. Infect. Dis. 74: 179-184.
14. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
15. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. Ratti, E. 1999. New frontiers in β-lactams: the trinems. In Proceedings of the 3rd International Antibacterial Drug Discovery and Development Summit, Princeton, N.J.
17. Tateda, K., K. Takashima, H. Miyazaki, T. Matsumoto, T. Hatori, and K. Yamaguchi. 1996. Noncompromised penicillin-resistant pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob. Agents Chemother. 40:1520-1525.
18. Woodnutt, G. 2000. Pharmacodynamics to combat resistance. J. Antimicrob. Chemother. 46:25-31.